Collection

Molecular Imaging in Neurodegeneration

The prevalence and incidence of neurogenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) are rapidly increasing with the aging society. Clinical assessment and traditional imaging techniques offer limited accuracy in the early and differential diagnosis of neurodegenerative diseases. Molecular imaging, including positron emission tomography (PET) and single photon emission computed tomography (SPECT), provides precision approaches to facilitate the diagnosis of neurogenerative diseases. This collection aims to present the results of molecular imaging in neurodegeneration, including the development of radiotracers, interesting results from new tracers, new methods for data analysis, and new findings in neurodegeneration with molecular imaging approaches.

Editors

  • Fang Xie, PhD

    Department of Nuclear Medicine & PET center, Huashan Hospital, Fudan University, China. His research interests include the development of radiotracers for cancer and brain disorders, neuroimaging and biomarkers of early signs of neurodegenerations He led translation of more than 10 radiotracers at Huahsan Hospital. He also led the establishment of a Chinese local AD cohort (C-PAS, Chinese preclinical Alzheimer’s Disease study) with more than 2000 amyloid PET scans and various other PET scans, including tau, SV2A, and mGluR5 PET.

  • Ruiqing Ni, PhD

    Institute for Regenerative Medicine and Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Switzerland. Her research focuses on the development of imaging biomarkers targeting amyloid-beta, tau and neuroinflammation for the early detection of Alzheimer’s disease and Parkinson’s disease and multiscale preclinical imaging techniques. She completed a PhD in Medical Science at Karolinska Institutet and postdoctoral training at the National Institute of Radiological Sciences (JSPS fellowship) and ETH Zurich.

Articles (21 in this collection)